Application No.: 09/762,106

Page 2

## IN THE CLAIMS:

Claim 1 (currently amended): An amide derivative of the Formula I

$$Q \xrightarrow{O} \overset{R^3}{\underset{O}{\overset{(R^2)_p}{\bigvee}}} H$$

wherein

R<sup>3</sup> is (1-6C)alkyl or halogeno;

Q is phenyl or naphthyl which optionally bears 1, 2, 3 or 4 substituents selected from

hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl,

formyl, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)alkylenedioxy,

(1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino,

di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,

 $\underline{N,N}\text{-di-}[(1\text{-}6C)alkyl] carbamoyl, (2\text{-}6C)alkanoyl, (2\text{-}6C)alkanoyloxy,$ 

 $(1-6C) alkanoylamino, \underline{N} - (1-6C) alkylsulphamoyl, \underline{N}, \underline{N} - di - [(1-6C) alkyl] sulphamoyl,$ 

(1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino,

halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl,

cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl,

di-[(1-6C)alkyl]amino-(1-6C)alkyl, carboxy-(1-6C)alkyl,

(1-6C)alkoxycarbonyl-(1-6C)alkyl, carbamoyl-(1-6C)alkyl,

 $\underline{N}$ -(1-6C)alkylcarbamoyl-(1-6C)alkyl,  $\underline{N}$ ,  $\underline{N}$ -di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl,

halogeno-(2-6C)alkoxy, hydroxy-(2-6C)alkoxy, (1-6C)alkoxy-(2-6C)alkoxy,

cyano-(1-6C)alkoxy, carboxy-(1-6C)alkoxy, (1-6C)alkoxycarbonyl-(1-6C)alkoxy,

 $carbamoyl \hbox{-} (1\hbox{-}6C) alkoxy, \underline{N} \hbox{-} (1\hbox{-}6C) alkyl carbamoyl \hbox{-} (1\hbox{-}6C) alkoxy,$ 

N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkoxy, amino-(2-6C)alkoxy,

(1-6C)alkylamino-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy,

halogeno-(2-6C)alkylamino, hydroxy-(2-6C)alkylamino,

(1-6C)alkoxy-(2-6C)alkylamino, cyano-(1-6C)alkylamino, carboxy-(1-6C)alkylamino,

(1-6C)alkoxycarbonyl-(1-6C)alkylamino, carbamoyl-(1-6C)alkylamino,

N-(1-6C)alkylcarbamoyl-(1-6C)alkylamino,

N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkylamino, amino-(2-6C)alkylamino,

(1-6C)alkylamino-(2-6C)alkylamino, di-[(1-6C)alkyl]amino-(2-6C)alkylamino,

N-(1-6C)alkyl-halogeno-(1-6C)alkylamino, N-(1-6C)alkyl-hydroxy-(2-6C)alkylamino,

N-(1-6C)alkyl-(1-6C)alkoxy-(2-6C)alkylamino,

 $\underline{N}$ -(1-6C)alkyl-cyano-(1-6C)alkylamino,  $\underline{N}$ -(1-6C)alkyl-carboxy-(1-6C)alkylamino,

N-(1-6C)alkyl-(1-6C)alkoxycarbonyl-(1-6C)alkylamino, N-(1-6C)alkyl-carbamoyl-

(1-6C)alkylamino, N-(1-6C)alkyl-N-(1-6C)alkylcarbamoyl-(1-6C)alkylamino,

N-(1-6C)alkyl-N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkylamino,

N-(1-6C)alkyl-amino-(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino-

(2-6C)alkylamino, N-(1-6C)alkyl-di-[(1-6C)alkyl]amino-(2-6C)alkylamino,

halogeno-(2-6C)alkanoylamino, hydroxy-(2-6C)alkanoylamino,

(1-6C)alkoxy-(2-6C)alkanoylamino, cyano-(2-6C)alkanoylamino,

carboxy-(2-6C)alkanoylamino, (1-6C)alkoxycarbonyl-(2-6C)alkanoylamino,

carbamoyl-(2-6C)alkanoylamino, N-(1-6C)alkylcarbamoyl-(2-6C)alkanoylamino,

N,N-di-[(1-6C)alkyl]carbamoyl-(2-6C)alkanoylamino, amino-(2-6C)alkanoylamino,

(1-6C)alkylamino-(2-6C)alkanoylamino, di-[(1-6C)alkyl]amino-(2-6C)alkanoylamino,

aryl, aryl-(1-6C)alkyl, aryl-(1-6C)alkoxy, aryloxy, arylamino,

N-(1-6C)alkyl-arylamino, aryl-(1-6C)alkylamino,

N-(1-6C)alkyl-aryl-(1-6C)alkylamino, aroylamino, arylsulphonylamino,

N-arylsulphamoyl, aryl-(2-6C)alkanoylamino, heteroaryl, heteroaryl-(1-6C)alkyl,

heteroaryloxy, heteroaryl-(1-6C)alkoxy, heteroarylamino,

N-(1-6C)alkyl-heteroarylamino, heteroaryl-(1-6C)alkylamino,

 $\underline{N}$ -(1-6C)alkyl-heteroaryl-(1-6C)alkylamino, heteroarylcarbonylamino,

heteroarylsulphonylamino, N-heteroarylsulphamoyl, heteroaryl-(2-6C)alkanoylamino,

heterocyclyl, heterocyclyl-(1-6C)alkyl, heterocyclyloxy, heterocyclyl-(1-6C)alkoxy,

heterocyclylamino,  $\underline{N}$ -(1-6C)alkyl-heterocyclylamino, heterocyclyl-(1-6C)alkylamino,  $\underline{N}$ -(1-6C)alkyl-heterocyclyl-(1-6C)alkylamino, heterocyclylcarbonylamino, heterocyclylsulphonylamino,  $\underline{N}$ -heterocyclylsulphamoyl and heterocyclyl-(2-6C)alkanoylamino,

and wherein any of the substituents on Q defined hereinbefore which comprise a CH<sub>2</sub> group which is attached to 2 carbon atoms or a CH<sub>3</sub> group which is attached to a carbon atom may optionally bear on each said CH<sub>2</sub> or CH<sub>3</sub> group a substituent selected from hydroxy, amino, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino and heterocyclyl;

and wherein any aryl, heteroaryl or heterocyclyl group in a substituent on Q may optionally bear 1 or 2 substituents selected from hydroxy, halogeno, (1-6C)alkyl, (1-6C)alkoxy, carboxy, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N-(1-6C)alkylcarbamoyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, aryl and aryl-(1-6C)alkyl;

R<sup>2</sup> is hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, (1-6C)alkoxycarbonyl, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylamino or di-[(1-6C)alkyl]amino;

p is 0, 1 or 2;

q is 0, 1, 2, 3 or 4; and

R<sup>4</sup> is aryl, aryl-(1-6C)alkoxy, aryloxy, <u>N</u>-(1-6C)alkyl-arylamino, aryl-(1-6C)alkylamino, <u>N</u>-(1-6C)alkyl-aryl-(1-6C)alkylamino, aroylamino, arylsulphonylamino, <u>N</u>-arylsulphamoyl, aryl-(2-6C)alkanoylamino, cycloalkyl, heteroaryl, heteroaryloxy, heteroaryl-(1-6C)alkoxy, heteroarylamino, <u>N</u>-(1-6C)alkyl-heteroarylamino, heteroaryl-(1-6C)alkylamino, <u>N</u>-(1-6C)alkyl-heteroaryl-(1-6C)alkylamino, heteroarylsulphonylamino, <u>N</u>-heteroarylsulphamoyl, heteroaryl-(2-6C)alkanoylamino, heterocyclyl, heterocyclyloxy, heterocyclyl-(1-6C)alkylamino, heterocyclylamino, <u>N</u>-(1-6C)alkyl-heterocyclylamino, heterocyclyl-(1-6C)alkylamino,

N-(1-6C)alkyl-heterocyclyl-(1-6C)alkylamino, heterocyclylcarbonylamino,

heterocyclylsulphonylamino, N-heterocyclylsulphamoyl or

heterocyclyl-(2-6C)alkanoylamino and R<sup>4</sup> optionally bears 1, 2, 3 or 4 substituents selected from

hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl,

formyl, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)alkylenedioxy,

(1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino,

di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,

N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy,

(1-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl,

(1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino,

halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl,

cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl,

di-[(1-6C)alkyl]amino-(1-6C)alkyl, carboxy-(1-6C)alkyl,

(1-6C)alkoxycarbonyl-(1-6C)alkyl, carbamoyl-(1-6C)alkyl,

 $\underline{N}$ -(1-6C)alkylcarbamoyl-(1-6C)alkyl,  $\underline{N}$ -di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl,

halogeno-(2-6C)alkoxy, hydroxy-(2-6C)alkoxy, (1-6C)alkoxy-(2-6C)alkoxy,

cyano-(1-6C)alkoxy, carboxy-(1-6C)alkoxy, (1-6C)alkoxycarbonyl-(1-6C)alkoxy,

carbamoyl-(1-6C)alkoxy, N-(1-6C)alkylcarbamoyl-(1-6C)alkoxy,

N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkoxy, amino-(2-6C)alkoxy,

(1-6C)alkylamino-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy,

halogeno-(2-6C)alkylamino, hydroxy-(2-6C)alkylamino,

(1-6C)alkoxy-(2-6C)alkylamino, cyano-(1-6C)alkylamino, carboxy-(1-6C)alkylamino,

(1-6C)alkoxycarbonyl-(1-6C)alkylamino, carbamoyl-(1-6C)alkylamino,

N-(1-6C)alkylcarbamoyl-(1-6C)alkylamino,

N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkylamino, amino-(2-6C)alkylamino,

(1-6C)alkylamino-(2-6C)alkylamino, di-[(1-6C)alkyl]amino-(2-6C)alkylamino,

N-(1-6C)alkyl-halogeno-(1-6C)alkylamino, N-(1-6C)alkyl-hydroxy-(2-6C)alkylamino,

N-(1-6C)alkyl-(1-6C)alkoxy-(2-6C)alkylamino,

N-(1-6C)alkyl-cyano-(1-6C)alkylamino, N-(1-6C)alkyl-carboxy-(1-6C)alkylamino,

 $\underline{N}$ -(1-6C)alkyl-(1-6C)alkoxycarbonyl-(1-6C)alkylamino,  $\underline{N}$ -(1-6C)alkyl-carbamoyl-

(1-6C)alkylamino,  $\underline{N}$ -(1-6C)alkyl- $\underline{N}$ -(1-6C)alkylcarbamoyl-(1-6C)alkylamino,

 $\underline{N}$ -(1-6C)alkyl- $\underline{N}$ ,  $\underline{N}$ -di-[(1-6C)alkyl]carbamoyl-(1-6C)alkylamino,

N-(1-6C)alkyl-amino-(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino-

(2-6C)alkylamino, N-(1-6C)alkyl-di-[(1-6C)alkyl]amino-(2-6C)alkylamino,

halogeno-(2-6C)alkanoylamino, hydroxy-(2-6C)alkanoylamino,

(1-6C)alkoxy-(2-6C)alkanoylamino, cyano-(2-6C)alkanoylamino,

carboxy-(2-6C)alkanoylamino, (1-6C)alkoxycarbonyl-(2-6C)alkanoylamino,

carbamoyl-(2-6C)alkanoylamino, N-(1-6C)alkylcarbamoyl-(2-6C)alkanoylamino,

N,N-di-[(1-6C)alkyl]carbamoyl-(2-6C)alkanoylamino, amino-(2-6C)alkanoylamino,

 $(1-6C) alkylamino-(2-6C) alkanoylamino, \\ di-[(1-6C)alkyl] amino-(2-6C) alkanoylamino, \\ di-[(1-6C)alkyl] amino-(2-6C$ 

aryl, aryl-(1-6C)alkyl, aryl-(1-6C)alkoxy, aryloxy, arylamino,

N-(1-6C)alkyl-arylamino, aryl-(1-6C)alkylamino,

N-(1-6C)alkyl-aryl-(1-6C)alkylamino, aroylamino, arylsulphonylamino,

N-arylsulphamoyl, aryl-(2-6C)alkanoylamino, heteroaryl, heteroaryl-(1-6C)alkyl,

heteroaryloxy, heteroaryl-(1-6C)alkoxy, heteroarylamino,

N-(1-6C)alkyl-heteroarylamino, heteroaryl-(1-6C)alkylamino,

N-(1-6C)alkyl-heteroaryl-(1-6C)alkylamino, heteroarylcarbonylamino,

heteroarylsulphonylamino, N-heteroarylsulphamoyl, heteroaryl-(2-6C)alkanoylamino,

heterocyclyl, heterocyclyl-(1-6C)alkyl, heterocyclyloxy, heterocyclyl-(1-6C)alkoxy,

heterocyclylamino, N-(1-6C)alkyl-heterocyclylamino, heterocyclyl-(1-6C)alkylamino,

N-(1-6C)alkyl-heterocyclyl-(1-6C)alkylamino, heterocyclylcarbonylamino,

eterocyclyl<br/>sulphonylamino,  $\underline{\textbf{N}}\text{-}\text{heterocyclylsulphamoyl}$  and

heterocyclyl-(2-6C)alkanoylamino,

and wherein any of the substituents on R<sup>4</sup> defined hereinbefore which comprise a CH<sub>2</sub> group which is attached to 2 carbon atoms or a CH<sub>3</sub> group which is attached to a carbon atom may optionally bear on each said CH<sub>2</sub> or CH<sub>3</sub> group a substituent selected from hydroxy, amino, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino and heterocyclyl;

1-WA/1973526.1

Application No.: 09/762,106

Page 7

and wherein any aryl, heteroaryl or heterocyclyl group in a substituent on R<sup>4</sup> may optionally bear 1 or 2 substituents selected from hydroxy, halogeno, (1-6C)alkyl, (1-6C)alkoxy, carboxy, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N-(1-6C)alkylcarbamoyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, aryl and aryl-(1-6C)alkyl;

or a pharmaceutically-acceptable salt or <u>in-vivo</u>-cleavable ester thereof <u>formed on an</u> available carboxy or hydroxy group;

except that the compounds:-

N-(2-cyclohexylethyl)-3-(4-hydroxybenzamido)-4-methylbenzamide,

3-(4-aminobenzamido)-N-(4-carboxy-3-hydroxyphenyl)-4-methylbenzamide,

N-(4-carboxy-3-hydroxyphenyl)-4-methyl-3-(4-nitrobenzamido)benzamide,

3-(4-aminobenzamido)-4-methyl-N-(2-pyridyl)benzamide,

4-methyl-3-(4-nitrobenzamido)-N-(2-pyridyl)benzamide,

 $3-(4-aminobenzamido)-4-methyl-\underline{N}-(2-thiazolyl)$ benzamide,

 $\hbox{4-methyl-3-(4-nitrobenzamido)-}\underline{\hbox{N-(2-thiazolyl)}} benzamide,$ 

3-benzamido-4-chloro-N-(2-fluoroanilino)benzamide,

3-(2-hydroxy-4-methylbenzamido)-N-(4-hydroxyphenyl)-4-methylbenzamide,

 $3-(3-hydroxy-2-naphthoylamino)-4-methyl-\underline{N}-phenylbenzamide and$ 

 $\label{eq:chloro-3-(3-hydroxy-2-naphthoylamino)-2-methyl-} \underline{N}\mbox{-phenylbenzamide are excluded}.$ 

Claim 2 (previously amended): An amide derivative of the Formula I according to claim 1 wherein

R<sup>3</sup> is methyl, ethyl, chloro or bromo;

Q is phenyl which bears 1, 2 or 3 substituents selected from hydroxy, fluoro, chloro, trifluoromethyl, cyano, carboxy, methyl, ethyl, propyl, methoxy, ethoxy, methylenedioxy, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, acetyl, propionyl, chloromethyl, methoxymethyl, methylaminomethyl, ethylaminomethyl,

dimethylaminomethyl, diethylaminomethyl, 2-chloroethoxy, 3-chloropropoxy, 2hydroxyethoxy, 3-hydroxypropoxy, 2-methoxyethoxy, 2-ethoxyethoxy, 3methoxypropoxy, 3-ethoxypropoxy, cyanomethoxy, carboxymethoxy, methoxycarbonylmethoxy, ethoxycarbonylmethoxy, tert-butoxycarbonylmethoxy, 2-aminoethoxy, 3-aminopropoxy, 2-methylaminoethoxy, 2-ethylaminoethoxy, 3-methylaminopropoxy, 3-ethylaminopropoxy, 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 3-dimethylaminopropoxy, 3-diethylaminopropoxy, 2-pyridylmethoxy, 2-(imidazol-1-yl)ethoxy, 3-(imidazol-1-yl)propoxy, pyrrolidin-1-yl, piperidino, morpholino, piperazin-1-yl, 4-methylpiperazin-1-yl, 4-acetylpiperazin-1-yl, pyrrolidin-1-ylmethyl, piperidinomethyl, morpholinomethyl, piperazin-1-ylmethyl, 4-methylpiperazin-1-ylmethyl, 4acetylpiperazin-1-ylmethyl, piperidin-4-yloxy, 1-methylpiperidin-4-yloxy, 2-(pyrrolidin-1-yl)ethoxy, 3-(pyrrolidin-1-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 2morpholinoethoxy, 3-morpholinopropoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1ylpropoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 2-(4-acetylpiperazin-1-yl)ethoxy and 3-(4-acetylpiperazin-1-yl)propoxy; p is 0;

ŊΙ

q is 0; and

R<sup>4</sup> is phenyl which bears 1 or 2 substituents selected from hydroxy, fluoro, chloro, trifluoromethyl, cyano, amino, methyl, ethyl, methoxy, ethoxy, methylenedioxy, methylamino, ethylamino, dimethylamino, diethylamino, acetyl, propionyl, chloromethyl, methoxymethyl, 2-methoxyethyl, methylaminomethyl, ethylaminomethyl, dimethylaminomethyl, diethylaminomethyl, 2-chloroethoxy, 3-chloropropoxy, 2-hydroxyethoxy, 3-hydroxypropoxy, 2-methoxyethoxy, 2-ethoxyethoxy, 3-methoxypropoxy, 3-ethoxypropoxy, cyanomethoxy, carboxymethoxy, methoxycarbonylmethoxy, ethoxycarbonylmethoxy, tert-butoxycarbonylmethoxy, 2-aminoethoxy, 3-aminopropoxy, 2-methylaminoethoxy, 2-ethylaminoethoxy, 3-methylaminopropoxy, 3-ethylaminopropoxy, 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 3-dimethylaminopropoxy, 3-diethylaminopropoxy, 2-chloroethylamino, 2-hydroxyethylamino, 2-methoxyethylamino, 2-ethoxyethylamino,

2-aminoethylamino, 2-methylaminoethylamino, 2-ethylaminoethylamino,

2-dimethylaminoethylamino, 2-diethylaminoethylamino, N-(2-chloroethyl)-N-

methylamino,  $\underline{N}$ -(2-hydroxyethyl)- $\underline{N}$ -methylamino,  $\underline{N}$ -(2-methoxyethyl)- $\underline{N}$ -methylamino,

N-(2-ethoxyethyl)-N-methylamino, N-(2-aminoethyl)-N-methylamino,

 $\underline{N}$ -(2-methylaminoethyl)- $\underline{N}$ -methylamino,  $\underline{N}$ -(2-dimethylaminoethyl)- $\underline{N}$ -methylamino,

 $\underline{N}$ -(3-aminopropyl)- $\underline{N}$ -methylamino,  $\underline{N}$ -(3-methylaminopropyl)- $\underline{N}$ -methylamino,

 $\underline{N}$ -(3-ethylaminopropyl)- $\underline{N}$ -methylamino,  $\underline{N}$ -(3-dimethylaminopropyl)- $\underline{N}$ -methylamino,

N-(3-diethylaminopropyl)-N-methylamino, phenyl, benzyl, benzyloxy,

2-pyridylmethoxy, 2-(imidazol-1-yl)ethoxy, 3-(imidazol-1-yl)propoxy, pyrrolidin-1-yl,

piperidino, morpholino, piperazin-1-yl, 4-methylpiperazin-1-yl, 4-acetylpiperazin-1-yl,

pyrrolidin-1-ylmethyl, piperidinomethyl, morpholinomethyl, piperazin-1-ylmethyl,

4-methylpiperazin-1-ylmethyl, 4-acetylpiperazin-1-ylmethyl, piperidin-4-yloxy,

1-methylpiperidin-4-yloxy, 2-(pyrrolidin-1-yl)ethoxy,

3-(pyrrolidin-1-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy,

2-morpholinoethoxy, 3-morpholinopropoxy, 2-piperazin-1-ylethoxy,

3-piperazin-1-ylpropoxy, 2-(4-methylpiperazin-1-yl)ethoxy,

3-(4-methylpiperazin-1-yl)propoxy, 2-(4-acetylpiperazin-1-yl)ethoxy and

3-(4-acetylpiperazin-1-yl)propoxy;

or a pharmaceutically-acceptable salt thereof;

except that 3-(2-hydroxy-4-methylbenzamido)-<u>N</u>-(4-hydroxyphenyl)-4-methylbenzamide is excluded.

Claim 3 (original, previously reformatted): An amide derivative of the Formula I according to claim 1 wherein


R<sup>3</sup> is methyl or chloro;

Q is phenyl which bears 1, 2 or 3 substituents selected from hydroxy, cyano, carboxy, methyl, ethyl, propyl, methoxy, ethoxy, acetyl and 2-methoxyethoxy;

p is 0;

q is 0; and

R<sup>4</sup> is phenyl which bears 1 or 2 substituents selected from chloro, cyano and dimethylamino;



Application No.: 09/762,106

Page 10

or a pharmaceutically-acceptable salt thereof.

Claim 4 (cancelled).

Claim 5 (original): An amide derivative of the Formula I according to claim 1 wherein Q is substituted by a basic substituent selected from the substituents for Q defined in claim 1 and R<sup>4</sup> is a phenyl or heteroaryl group as defined in claim 1 which also bears a basic substituent selected from the substituents for R<sup>4</sup> defined in claim 1.

Claim 6 (original, previously reformatted): An amide derivative of the Formula I according to claim 1 wherein

R<sup>3</sup> is methyl or chloro;

O is phenyl which bears a substituent selected from dimethylaminomethyl, diethylaminomethyl, N-butyl-N-methylaminomethyl, 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 2-diisopropylaminoethoxy, 3-dimethylaminopropoxy, 3-diethylaminopropoxy, 3-diisopropylaminopropoxy, pyrrolidin-1-ylmethyl, 3-hydroxypyrrolidin-1-ylmethyl, morpholinomethyl, piperidinomethyl, homopiperidinomethyl, piperazin-1-ylmethyl, homopiperazin-1-ylmethyl, 4methylpiperazin-1-ylmethyl, 4-methylhomopiperazin-1-ylmethyl, 4-ethylpiperazin-1ylmethyl, 4-ethylhomopiperazin-1-ylmethyl, 4-isopropylpiperazin-1-ylmethyl, 4-(2-hydroxyethyl)piperazin-1-ylmethyl, 2-pyridylmethoxy, pyrrolidin-3-yloxy, 1-methylpyrrolidin-3-yloxy, piperidin-3-yloxy, 1-methylpiperidin-3-yloxy, homopiperidin-3-yloxy, 1-methylhomopiperidin-3-yloxy, piperidin-4-yloxy, 1methylpiperidin-4-yloxy, homopiperidin-4-yloxy, 1-methylhomopiperidin-4-yloxy, pyrrolidin-3-ylmethoxy, 1-methylpyrrolidin-3-ylmethoxy, piperidin-3-ylmethoxy, 1methylpiperidin-3-ylmethoxy, homopiperidin-3-ylmethoxy, 1-methylhomopiperidin-3ylmethoxy, piperidin-4-ylmethoxy, 1-methylpiperidin-4-ylmethoxy, homopiperidin-4ylmethoxy, 1-methylhomopiperidin-4-ylmethoxy, 2-(pyrrolidin-1-yl)ethoxy, 3-(pyrrolidin-1-yl)propoxy, 2-(N-methylpyrrolidin-2-yl)ethoxy, 3-(N-methylpyrrolidin-2-yl)ethoxy, 3-(N-methylpyrrolidin-2-y

yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-piperazin-1-ylethoxy, 2-homopiperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 3-homopiperazin-1-ylpropoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 2-(4-methylhomopiperazin-1-yl)pthoxy, 3-(4-methylhomopiperazin-1-yl)propoxy, 3-(4-methylhomopiperazin-1-yl)propoxy, 2-(4-acetylpiperazin-1-yl)ethoxy, 3-(4-acetylpiperazin-1-yl)propoxy, 2-methoxyethylaminomethyl, 3-methoxypropylaminomethyl, 2-aminoethylaminomethyl, 3-aminopropylaminomethyl, 3-dimethylamino-2,2-dimethylpropylaminomethyl, 2-methylaminoethylaminomethyl, 3-methylaminopropylaminomethyl, N-(2-methylaminoethyl)-N-methylaminomethyl, N-(3-methylaminopropyl)-N-methylaminomethyl, N-(2-dimethylaminomethyl)-N-methylaminomethyl, N-(3-dimethylaminopropyl)-N-methylaminomethyl and 3-morpholinopropylaminomethyl, and Q is optionally substituted with a further substituent selected from methyl and methoxy;

p is 0;

q is 0; and

R<sup>4</sup> is phenyl which is substituted at the 3-position with a substituent selected from dimethylamino, diethylamino, pyrrolidin-1-yl, piperidino, morpholino, piperazin-1-yl, homopiperazin-1-yl, 4-methylpiperazin-1-yl and 4-methylhomopiperazin-1-yl and R<sup>4</sup> is optionally substituted with a further substituent selected from fluoro, chloro, cyano, methyl and trifluoromethyl;

or a pharmaceutically-acceptable salt thereof.

Claim 7 (cancelled).

Claim 8 (previously amended): An amide derivative of the Formula I according to claim 1 selected from :-

N-(3-dimethylaminophenyl)-4-methyl-3-(4-propylbenzamido)benzamide,

 $3\hbox{-}(3,4\hbox{-}dimethoxy benzamido)\hbox{-}\underline{N}\hbox{-}(3\hbox{-}dimethylamin ophenyl)\hbox{-}4\hbox{-}methylbenzamide,$ 

3-(4-butoxybenzamido)-N-(3-dimethylaminophenyl)-4-methylbenzamide,

4-chloro-N-(3-dimethylaminophenyl)-3-(4-propylbenzamido)benzamide,

3-(4-carboxybenzamido)-N-(3-dimethylaminophenyl)-4-methylbenzamide,

N-(3,4-dichlorobenzyl)-3-(3,4,5-trimethoxybenzamido)-4-methylbenzamide,

N-(2-cyclohexylethyl)-3-(3,4-dimethoxybenzamido)-4-methylbenzamide,

4-methyl-N-(3-morpholinophenyl)-3-(3-piperidin-4-yloxybenzamido)benzamide,

 $\hbox{$4$-chloro-$\underline{N}$-(3-fluoro-5-morpholinophenyl)-$3-[3-(1-methylhomopiperidin-morpholinophenyl)-$3-[3-(1-methylhomopiperidin-morpholinophenyl)-$3-[3-(1-methylhomopiperidin-morpholinophenyl)-$3-[3-(1-methylhomopiperidin-morpholinophenyl)-$3-[3-(1-methylhomopiperidin-morpholinophenyl)-$3-[3-(1-methylhomopiperidin-morpholinophenyl)-$3-[3-(1-methylhomopiperidin-morpholinophenyl)-$3-[3-(1-methylhomopiperidin-morpholinophenyl)-$3-[3-(1-methylhomopiperidin-morpholinophenyl)-$3-[3-(1-methylhomopiperidin-morpholinophenyl)-$3-[3-(1-methylhomopiperidin-morpholinophenyl)-$3-[3-(1-methylhomopiperidin-morpholinophenyl)-$3-[3-(1-methylhomopiperidin-morpholinophenyl)-$3-[3-(1-methylhomopiperidin-morpholinophenyl)-$3-[3-(1-methylhomopiperidin-morpholinophenyl]-$4-(1-methylhomopiperidin-morpholinophenyl)-$4-(1-methylh$ 

4-yloxy)benzamido]benzamide,

3-(2-diisopropylaminoethoxybenzamido)-4-methyl-N-(3-morpholinophenyl)benzamide,

3-(4-diethylaminomethylbenzamido)-4-methyl-N-(3-morpholinophenyl)benzamide,

4-methyl-3-[3-(4-methylhomopiperazin-1-ylmethyl)benzamido]-N-(3-morpholinophenyl)-

benzamide, and

4-methyl-3-[3-(4-methylpiperazin-1-ylmethyl)benzamido]- $\underline{N}$ -(3-morpholinophenyl)-benzamide;

or a pharmaceutically-acceptable salt thereof.

Claim 9 (currently amended): A process for the preparation of an amide derivative of the Formula I, or a pharmaceutically-acceptable salt or <u>in vivo</u>-in-vivo-cleavable ester thereof formed on an available carboxy or hydroxy group, according to claim 1 which comprises:-

(a) reacting a benzoic acid of the Formula II, or a reactive derivative thereof,

$$Q \xrightarrow{\mathsf{N}} \mathsf{R}^3$$
 $\mathsf{CO}_2\mathsf{H}$ 
II

with an amine of the Formula III

$$H_2N \longrightarrow (CH_2)_q \longrightarrow R^4$$
 III

under standard amide bond forming conditions, wherein variable groups are as defined in claim 1 and wherein any functional group is protected if necessary, and:

- (i) removing any protecting groups; and
- (ii) optionally forming a pharmaceutically-acceptable salt or in vivo-in-vivocleavable ester on an available carboxy or hydroxy group;
- (b) reacting an acid of the Formula IV, or an activated derivative thereof,

$$Q \longrightarrow Q \longrightarrow Q$$
 IV

with an aniline of the Formula VI

$$H_2N$$
 $H_2N$ 
 $H_2N$ 
 $H$ 
 $O$ 
 $(CH_2)_q$ 
 $R^4$ 
 $VI$ 

under standard amide bond forming conditions as defined hereinbefore, wherein variable groups are as defined in claim 1 and wherein any functional group is protected, if necessary, and:

- (i) removing any protecting groups;
- (ii) optionally forming a pharmaceutically-acceptable salt or in vivo in vivo cleavable ester on an available carboxy or hydroxy group;
- (c) for the preparation of a compound of the Formula I wherein a substituent on Q or R<sup>4</sup> is (1-6C)alkoxy or substituted (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylamino, di-[(1-6C)alkyl]amino or substituted (1-6C)alkylamino or heterocyclyloxy, the alkylation, conveniently in the presence of a suitable base, of an amide derivative of the Formula I wherein a substituent on O or R<sup>4</sup> is hydroxy, mercapto or amino as appropriate;
- (d) for the preparation of a compound of the Formula I wherein a substituent on Q or R<sup>4</sup> is (1-6C)alkanoylamino or substituted (2-6C)alkanoylamino, the acylation of a compound of the Formula I wherein a substituent on O or R<sup>4</sup> is amino;
- (e) for the preparation of a compound of the Formula I wherein a substituent on Q or R<sup>4</sup>

is (1-6C)alkanesulphonylamino, the reaction of a compound of the Formula I wherein a substituent on Q or R<sup>4</sup> is amino with a (1-6C)alkanesulphonic acid, or an activated derivative thereof;

- (f) for the preparation of a compound of the Formula I wherein a substituent on Q or R<sup>4</sup> is carboxy, carboxy-(1-6C)alkyl, carboxy-(1-6C)alkoxy, carboxy-(1-6C)alkylamino, N-(1-6C)alkyl-carboxy-(1-6C)alkylamino or carboxy-(2-6C)alkanoylamino, the cleavage of a compound of the Formula I wherein a substituent on Q or R<sup>4</sup> is (1-6C)alkoxycarbonyl, (1-6C)alkoxycarbonyl-(1-6C)alkyl, (1-6C)alkoxycarbonyl-(1-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkoxycarbonyl-(1-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkoxycarbonyl-(1-6C)alkylamino or (1-6C)alkoxycarbonyl-(2-6C)alkanoylamino as appropriate;
- (g) for the preparation of a compound of the Formula I wherein a substituent on Q or R<sup>4</sup> is amino-(1-6C)alkyl, heterocyclyl-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, substituted (2-6C)alkylamino-(1-6C)alkyl or substituted N-(1-6C)alkyl-(2-6C)alkylamino-(1-6C)alkyl, the reaction of a compound of the Formula I wherein a substituent on Q or R<sup>4</sup> is a group of the formula -(1-6C)alkylene-Z wherein Z is a displaceable group with an appropriate amine or heterocyclyl compound;
- (h) for the preparation of a compound of the Formula I wherein a substituent on Q or R<sup>4</sup> is amino, heterocyclyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, substituted (1-6C)alkylamino, substituted N-(1-6C)alkyl-(1-6C)alkylamino, substituted (2-6C)alkylamino or substituted N-(1-6C)alkyl-(2-6C)alkylamino, the reaction of a compound of the Formula I wherein a substituent on Q or R<sup>4</sup> is a displaceable group Z with an appropriate amine or heterocyclyl compound;
- (i) for the preparation of a compound of the Formula I wherein a substituent on Q or R<sup>4</sup> is N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, the alkylation, conveniently in the presence of a suitable base, of an amide derivative of the Formula I wherein a substituent on Q or R<sup>4</sup> is (1-6C)alkanesulphonylamino;
- (j) for the preparation of a compound of the Formula I wherein a substituent on Q or R<sup>4</sup> is a hydroxy-heterocyclyl-(1-6C)alkoxy group, a hydroxy-(1-6C)alkylamino-(2-

6C)alkoxy group or a hydroxy-di-[(1-6C)alkyl]amino-(2-6C)alkoxy group, the reaction of a compound of the Formula I wherein a substituent on Q or R<sup>4</sup> is a epoxy-substituted (1-6C)alkoxy group with a heterocyclyl compound or an appropriate amine; or

(k) for the preparation of a compound of the Formula I wherein  $R^2$  or a substituent on Q or  $R^4$  is an amino group, the reduction of a compound of the Formula I wherein  $R^2$  or a substituent on Q or  $R^4$  is a nitro group.

Claim 10 (currently amended): A pharmaceutical composition which comprises an amide derivative of the Formula I, or a pharmaceutically-acceptable or <u>in vivo</u>-in-vivo-cleavable ester thereof <u>formed on an available carboxy or hydroxy group</u>, according to claim 1 in association with a pharmaceutically-acceptable diluent or carrier.

Claim 11 (cancelled).

Claim 12 (currently amended): A method for treating a disease or medical condition mediated by the production or effect of TNF, said method comprising administering to a warm-blooded animal in need thereof a TNF inhibiting amount of an amide derivative of the Formula I, or a pharmaceutically-acceptable salt or *in vivo* -in-vivo cleavable ester thereof formed on an available carboxy or hydroxy group, according to claim 1.

Claim 13 (currently amended): A method for treating a disease or medical condition mediated by the production or effect of IL-1, IL-6 or IL-8, said method comprising administering to a warm-blooded animal in need thereof an IL-1, IL-6 or IL-8 inhibiting amount of an amide derivative of the Formula I, or a pharmaceutically-acceptable salt or <u>in vivo</u> in-vivo cleavable ester thereof formed on an available carboxy or hydroxy group, according to claim 1.

Claim 14 (new): A method for inhibiting the production or effect of TNF or IL-1 in a warm-blooded animal in need thereof comprising administering to said animal a TNF or IL-1

inhibiting amount of an amide derivative of the Formula I, or a pharmaceutically-acceptable salt or <u>in-vivo</u>-cleavable ester thereof formed on an available carboxy or hydroxy group, as defined in claim 1.

Claim 15 (new): A method for producing a TNF inhibitory effect in a warm-blooded animal in need of thereof which comprises administering to said animal a TNF inhibiting amount of an amide derivative of the Formula I, or a pharmaceutically-acceptable salt or *in vivo* cleavable ester thereof formed on an available carboxy or hydroxy group, as defined in claim 1.

Claim 16 (new): A method for producing a p38 kinase inhibitory effect in a warm-blooded animal in need of thereof which comprises administering to said animal a p38 kinase inhibiting amount of an amide derivative of the Formula I, or a pharmaceutically-acceptable salt or *in vivo* cleavable ester thereof formed on an available carboxy or hydroxy group, as defined in claim 1.

Claim 17. (New) A method for producing an anti-inflammatory effect in a warm blooded animal in need thereof which comprises administering to said animal an anti-inflammatory effective amount of an amide derivative of the Formula I, or a pharmaceutically-acceptable salt or *in vivo* cleavable ester thereof formed on an available carboxy or hydroxy group, as defined in claim 1.

Claim 17 (New) A method for treating an inflammatory disease or medical condition in a warm blooded animal in need thereof which comprises administering to said animal an anti-inflammatory effective amount of an amide derivative of the Formula I, or a pharmaceutically-acceptable salt or *in vivo* cleavable ester thereof formed on an available carboxy or hydroxy group, as defined in claim 1.

Claim 18. (New) The method of claim 17 wherein said inflammatory disease or medical condition is rheumatoid arthritis.